FindTrial
Sign In

Single dose oral bioequivalence study of Cladribine 10 mg Tablets and Mavenclad® 10 mg tablets (Cladribine) in healthy adult human subjects under fed conditions

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522252-74-00
Acronym
CPO25001
Enrollment
40
Registered
2025-10-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No therapeutic indication in the current trial with healthy volunteers.

Interventions

None listed

Sponsors

PharOS Pharmaceutical Oriented Servises Ltd., CCDRD Cooperative Clinical Drug Research and Development AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Countries

Bulgaria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026